An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Venglustat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Genzyme
- 10 Jun 2017 Biomarkers information updated
- 04 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 26 May 2016 Planned End Date changed from 1 Mar 2019 to 1 Nov 2018.